David C. Chang's most recent trade in AXT Inc was a trade of 25,000 Common Stock done at an average price of $14.8 . Disclosure was reported to the exchange on Dec. 9, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| AXT Inc | David C. Chang | Director | Sale of securities on an exchange or to another person at price $ 14.84 per share. | 09 Dec 2025 | 25,000 | 132,744 (0%) | 0% | 14.8 | 371,025 | Common Stock |
| AXT Inc | David C. Chang | Director | Sale of securities on an exchange or to another person at price $ 12.33 per share. | 28 Nov 2025 | 25,000 | 157,744 (0%) | 0% | 12.3 | 308,250 | Common Stock |
| AXT Inc | David C. Chang | Director | Sale of securities on an exchange or to another person at price $ 10.72 per share. | 28 Nov 2025 | 25,000 | 182,744 (0%) | 0% | 10.7 | 268,000 | Common Stock |
| AXT Inc | David C. Chang | Director | Sale of securities on an exchange or to another person at price $ 8.94 per share. | 05 Nov 2025 | 100,000 | 207,744 (0%) | 0% | 8.9 | 894,040 | Common Stock |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 May 2025 | 185,709 | 0 | - | - | Stock Option (Right to Buy) | |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 185,709 | 185,709 | - | - | Stock Option (Right to Buy) | |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 May 2025 | 150,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 135,000 | 135,000 | - | - | Stock Option (Right to Buy) | |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 May 2025 | 135,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 130,000 | 130,000 | - | - | Stock Option (Right to Buy) | |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 May 2025 | 130,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 113,500 | 113,500 | - | - | Stock Option (Right to Buy) | |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 May 2025 | 113,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 May 2025 | 48,836 | 0 | - | - | Stock Option (Right to Buy) | |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 48,836 | 48,836 | - | - | Stock Option (Right to Buy) | |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 May 2025 | 38,238 | 0 | - | - | Stock Option (Right to Buy) | |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 38,238 | 38,238 | - | - | Stock Option (Right to Buy) | |
| AXT Inc | David C. Chang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 55,172 | 307,744 (0%) | 0% | - | Common Stock | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 1.96 per share. | 14 Mar 2025 | 46,668 | 5,276,569 (4%) | 0% | 2.0 | 91,469 | Common Stock |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 145,000 | 145,000 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 1.68 per share. | 03 Feb 2025 | 46,003 | 5,317,237 (4%) | 0% | 1.7 | 77,285 | Common Stock |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 1,952,130 | 1,952,130 | - | - | Stock Option (Right to buy) | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 552,174 | 5,363,240 (4%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.90 per share. | 16 May 2024 | 344,828 | 4,810,106 (3%) | 0% | 2.9 | 1,000,001 | Common Stock |
| AXT Inc | David C. Chang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 23,323 | 252,572 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.33 per share. | 14 Mar 2024 | 53,393 | 4,465,278 (3%) | 0% | 4.3 | 231,192 | Common Stock |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 130,000 | 130,000 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Chang D. David | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2024 | 1,123,535 | 1,123,535 | - | - | Stock Option (Right to buy) | |
| Allogene Therapeutics Inc | D. David Chang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2024 | 317,800 | 4,513,203 (3%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2023 | 1,924,464 | 4,193,911 (3%) | 1% | 0 | Common Stock | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2023 | 1,492,200 | 1,492,200 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.56 per share. | 14 Mar 2023 | 22,340 | 2,269,447 (1%) | 0% | 5.6 | 124,210 | Common Stock |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2023 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| AXT Inc | David C. Chang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2022 | 15,238 | 205,926 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Mar 2022 | 2,195,512 | 2,195,512 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 7.65 per share. | 15 Mar 2022 | 23,648 | 2,289,652 (1%) | 0% | 7.6 | 180,879 | Common Stock |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 135,000 | 135,000 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 May 2021 | 27,410 | 541,190 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.22 per share. | 24 May 2021 | 27,410 | 2,312,279 (1%) | 0% | 18.2 | 499,410 | Common Stock |
| AXT Inc | David C. Chang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 6,726 | 190,688 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Mar 2021 | 205,778 | 856,044 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Mar 2021 | 205,778 | 856,044 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | David D. Chang | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 38.57 per share. | 15 Mar 2021 | 20,513 | 2,204,417 (1%) | 0% | 38.6 | 791,271 | Common Stock |
| Cabaletta Bio Inc | David J. Chang | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 113,500 | 113,500 | - | - | Stock Option (Right to Buy) |